Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Biogen Inc (BIIB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 55,460,452
  • Shares Outstanding, K 211,560
  • Annual Sales, $ 12,274 M
  • Annual Income, $ 2,539 M
  • 36-Month Beta 0.86
  • Price/Sales 4.47
  • Price/Cash Flow 9.58
  • Price/Book 4.35

Price Performance

See More
Period Period Low Period High Performance
1-Month
249.17 +8.14%
on 04/24/18
276.44 -2.53%
on 03/29/18
+9.32 (+3.58%)
since 03/23/18
3-Month
249.17 +8.14%
on 04/24/18
370.57 -27.29%
on 01/26/18
-84.29 (-23.83%)
since 01/25/18
52-Week
244.28 +10.30%
on 05/31/17
370.57 -27.29%
on 01/26/18
-17.44 (-6.08%)
since 04/25/17

Most Recent Stories

More News
Biotech Stock Roundup: PRTA Down, AMGN Revises View, BIIB Misses on Sales

The biotech sector grabbed headlines last week as a couple of biotechs reported results while few others came out with pipeline updates.

LLY : 81.14 (+1.31%)
INCY : 62.99 (+1.03%)
IONS : 43.98 (-2.98%)
PRTA : 10.99 (-0.90%)
CALA : 5.90 (unch)
AMGN : 174.83 (+1.68%)
BIIB : 269.45 (+2.78%)
Biogen Inc Set to Possibly Pullback After Yesterday's Rally of 2.55%

Biogen Inc (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $262.27 to a high of $274.40. Yesterday, the shares gained 2.5%, which took the trading range above the 3-day high of $267.66...

BIIB : 269.45 (+2.78%)
Drug Stock Q1 Earnings Due on Apr 26: ABBV, ALXN, BMY & VRTX

Four pharma/biotech companies are set to release earnings report on Apr 26. Let's take a look into how the companies are placed ahead of the upcoming results.

JNJ : 126.76 (+0.45%)
VRTX : 155.15 (-0.33%)
NVS : 76.42 (-0.74%)
ABBV : 91.87 (+0.56%)
BMY : 51.76 (+0.35%)
ALXN : 106.04 (-0.44%)
BIIB : 269.45 (+2.78%)
Biogen (BIIB) Q1 Earnings Beat, Sales Miss, Shares Down

Biogen's (BIIB) earnings beat estimates but sales miss the same marginally in Q1. The company's latest key drug Spinraza's tepid sales compares with its sequential tally.

ABBV : 91.87 (+0.56%)
RHHBY : 27.8300 (-0.32%)
SNY : 40.11 (+0.91%)
BIIB : 269.45 (+2.78%)
Biotech Drug Production Pipeline Increasing Amid Buzz of Market Optimism

MarketNewsUpdates.com News Commentary

EBIO : 2.37 (+6.76%)
IONS : 43.98 (-2.98%)
INSM : 25.17 (+0.68%)
VRX : 17.54 (+0.40%)
MBRX : 1.83 (+2.23%)
BIIB : 269.45 (+2.78%)
Biogen (BIIB) Q1 Earnings Beat, Sales Miss

Biogen (BIIB) beat estimates for earnings but marginally misses the same for sales in Q1. The company's oral MS drug Tecfidera sales increased year over year.

BIIB : 269.45 (+2.78%)
Biogen Reports Quarterly Revenues of $3.1 Billion

--GAAP diluted EPS increased 60%; Non-GAAP EPS increased 16%

BIIB : 269.45 (+2.78%)
Drug/Biotech Stock Q1 Earnings Due on Apr 24: LLY, BIIB, AMGN

Three pharma/biotech bigwigs are set to release earnings report on Apr 24. Let's sneak a peek into how the companies are placed ahead of the upcoming results.

JNJ : 126.76 (+0.45%)
LLY : 81.14 (+1.31%)
NVS : 76.42 (-0.74%)
AMGN : 174.83 (+1.68%)
BIIB : 269.45 (+2.78%)
Roche (RHHBY) Presents Encouraging Data on MS Drug Ocrevus

Roche (RHHBY) announces encouraging data on multiple sclerosis (MS) drug Ocrevus which reinforced the efficacy of drug in the long run.

CELG : 89.20 (+0.07%)
NVS : 76.42 (-0.74%)
RHHBY : 27.8300 (-0.32%)
BIIB : 269.45 (+2.78%)
New SPINRAZA(R) (nusinersen) Data Unveiled at AAN Annual Meeting Show Continued Improvement in Motor Function for Broad Age Range and Survival Benefit for Infants

--Additional findings show that later-onset SMA patients treated with SPINRAZA walked longer distances while experiencing stable or less fatigue over time, in contrast to SMA natural history

IONS : 43.98 (-2.98%)
BIIB : 269.45 (+2.78%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia,...

See More

Key Turning Points

2nd Resistance Point 280.84
1st Resistance Point 275.14
Last Price 269.45
1st Support Level 263.01
2nd Support Level 256.58

See More

52-Week High 370.57
Fibonacci 61.8% 322.33
Fibonacci 50% 307.42
Fibonacci 38.2% 292.52
Last Price 269.45
52-Week Low 244.28

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar